259 related articles for article (PubMed ID: 35452622)
1. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
Ying B; Scheaffer SM; Whitener B; Liang CY; Dmytrenko O; Mackin S; Wu K; Lee D; Avena LE; Chong Z; Case JB; Ma L; Kim TTM; Sein CE; Woods A; Berrueta DM; Chang GY; Stewart-Jones G; Renzi I; Lai YT; Malinowski A; Carfi A; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
Cell; 2022 Apr; 185(9):1572-1587.e11. PubMed ID: 35452622
[TBL] [Abstract][Full Text] [Related]
2. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
[TBL] [Abstract][Full Text] [Related]
3. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
Lyke KE; Atmar RL; Islas CD; Posavad CM; Szydlo D; Paul Chourdhury R; Deming ME; Eaton A; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Archer JI; Crandon S; Zemanek JA; Brown ER; Neuzil KM; Stephens DS; Post DJ; Nayak SU; Suthar MS; Roberts PC; Beigel JH; Montefiori DC;
Cell Rep Med; 2022 Jul; 3(7):100679. PubMed ID: 35798000
[TBL] [Abstract][Full Text] [Related]
4. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
5. Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice.
Ying B; Scheaffer SM; Whitener B; Liang CY; Dmytrenko O; Mackin S; Wu K; Lee D; Avena LE; Chong Z; Case JB; Ma L; Kim T; Sein C; Woods A; Berrueta DM; Carfi A; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
bioRxiv; 2022 Feb; ():. PubMed ID: 35169795
[TBL] [Abstract][Full Text] [Related]
6. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
[TBL] [Abstract][Full Text] [Related]
7. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
[TBL] [Abstract][Full Text] [Related]
8. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.
Wang F; Huang B; Deng Y; Zhang S; Liu X; Wang L; Liu Q; Zhao L; Tang L; Wang W; Wang X; Ye F; Hu W; Yang H; Wang S; Ren J; Liu X; Wang C; Guan X; Wang R; Zheng Y; Zhang X; Zheng H; Wu D; An Z; Xu W; Rodewald LE; Gao GF; Yin Z; Tan W
BMC Med; 2023 Jul; 21(1):233. PubMed ID: 37400857
[TBL] [Abstract][Full Text] [Related]
10. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
Suntronwong N; Kanokudom S; Auphimai C; Assawakosri S; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Puenpa J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
J Med Virol; 2022 Dec; 94(12):5713-5722. PubMed ID: 35924475
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
Evans JP; Zeng C; Qu P; Faraone J; Zheng YM; Carlin C; Bednash JS; Zhou T; Lozanski G; Mallampalli R; Saif LJ; Oltz EM; Mohler PJ; Xu K; Gumina RJ; Liu SL
Cell Host Microbe; 2022 Aug; 30(8):1093-1102.e3. PubMed ID: 35526534
[TBL] [Abstract][Full Text] [Related]
12. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
13. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
14. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
15. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; Peng K-W; García-Sastre A; Schotsaert M; Russell SJ
mBio; 2024 Feb; 15(2):e0292823. PubMed ID: 38193729
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
[TBL] [Abstract][Full Text] [Related]
17. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
Evans JP; Zeng C; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
Sci Transl Med; 2022 Mar; 14(637):eabn8057. PubMed ID: 35166573
[TBL] [Abstract][Full Text] [Related]
19. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.
Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
bioRxiv; 2022 Sep; ():. PubMed ID: 36263060
[TBL] [Abstract][Full Text] [Related]
20. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]